PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY

• John Mascarenhas,
• Lei He,
• Rabih Saab,
• Nashat Gabrail,
• Keita Kirito,
• Deanna Brackman,
• Federico Innocenti

Affiliations

John Mascarenhas

1 Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, United States

Lei He

2 AbbVie Inc, Chicago, United States

Rabih Saab

2 AbbVie Inc, Chicago, United States

Nashat Gabrail

3 Gabrail Cancer Center, Department of Oncology, Canton, United States

Keita Kirito

4 University of Yamanashi, Department of Hematology and Oncology, Kofu, Japan

Deanna Brackman

2 AbbVie Inc, Chicago, United States

Federico Innocenti

2 AbbVie Inc, Chicago, United States